checkAd

    DGAP-News  457  0 Kommentare MagForce AG: MagForce USA, Inc. files Investigational Device Exemption for NanoTherm(TM) Therapy to Treat Intermediate Risk Prostate Cancer - Seite 2


    the USA.," Dr. Ben J. Lipps added.

    About MagForce AG and MagForce USA, Inc.

    MagForce AG, listed in the entry standard of the Frankfurt Stock Exchange
    (MF6, ISIN: DE000A0HGQF5), together with its subsidiary MagForce USA, Inc.
    is a leading medical device company in the field of nanomedicine focused on
    oncology. The Group's proprietary NanoTherm(TM) therapy enables the
    targeted treatment of solid tumors through the intratumoral generation of
    heat via activation of superparamagnetic nanoparticles. Mithril Capital
    Management, a growth-stage technology fund founded by Ajay Royan and Peter
    Thiel, along with MagForce AG, are investors and strategic partners in
    MagForce USA, Inc.

    NanoTherm(TM), NanoPlan(R), and NanoActivator(R) are components of the
    therapy and have received EU-wide regulatory approval as medical devices
    for the treatment of brain tumors. MagForce, NanoTherm(TM), NanoPlan(R),
    and NanoActivator(R) are trademarks of MagForce AG in selected countries.

    For more information, please visit: www.magforce.com
    Get to know our Technology: video (You Tube)
    Stay informed and subscribe to our mailing list.

    Disclaimer

    This release may contain forward-looking statements and information which
    may be identified by formulations using terms such as "expects", "aims",
    "anticipates", "intends", "plans", "believes", "seeks", "estimates" or
    "will". Such forward-looking statements are based on our current
    expectations and certain assumptions, which may be subject to a variety of
    risks and uncertainties. The results actually achieved by MagForce AG may
    substantially differ from these forward-looking statements. MagForce AG
    assumes no obligation to update these forward-looking statements or to
    correct them in case of developments, which differ from those, anticipated.

    Contact:
    MC Services AG
    Anne Hennecke

    P +49 211 529252-22
    F +49 211 529252-29

    E-mail: anne.hennecke@mc-services.eu



    ---------------------------------------------------------------------

    21.05.2015 Dissemination of a Corporate News, transmitted by DGAP - a
    service of EQS Group AG.
    The issuer is solely responsible for the content of this announcement.

    The DGAP Distribution Services include Regulatory Announcements,
    Financial/Corporate News and Press Releases.
    Media archive at www.dgap-medientreff.de and www.dgap.de

    ---------------------------------------------------------------------


    Language: English
    Company: MagForce AG
    Max-Planck-Straße 3
    12489 Berlin
    Germany
    Phone: +49 (0)30 308 380 0
    Fax: +49 (0)30 308 380 99
    E-mail: info@magforce.com
    Internet: www.magforce.com
    ISIN: DE000A0HGQF5
    WKN: A0HGQF
    Listed: Regulated Unofficial Market in Berlin, Dusseldorf,
    Stuttgart; Open Market (Entry Standard) in Frankfurt


    End of News DGAP News-Service
    ---------------------------------------------------------------------
    360293 21.05.2015
    Seite 2 von 2


    Diskutieren Sie über die enthaltenen Werte


    EQS Group AG
    0 Follower
    Autor folgen

    Verfasst von EQS Group AG
    DGAP-News MagForce AG: MagForce USA, Inc. files Investigational Device Exemption for NanoTherm(TM) Therapy to Treat Intermediate Risk Prostate Cancer - Seite 2 DGAP-News: MagForce AG / Key word(s): Miscellaneous MagForce AG: MagForce USA, Inc. files Investigational Device Exemption for NanoTherm(TM) Therapy to Treat Intermediate Risk Prostate Cancer 21.05.2015 / 07:15 …